A Closer Look at 5 Analyst Recommendations For Evolus
Portfolio Pulse from Benzinga Insights
In the last three months, five analysts have rated Evolus (NASDAQ:EOLS), with most being bullish. The average 12-month price target increased to $23.6, with a high of $27.00 and a low of $20.00. Evolus, a performance beauty company, has shown a 35.59% revenue growth rate but faces challenges with high debt and low ROE and ROA.
October 03, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus has received mostly bullish ratings from analysts, with an increased average price target of $23.6. The company shows strong revenue growth but faces financial challenges with high debt and low ROE and ROA.
The majority of analysts are bullish on Evolus, with an increased price target indicating positive sentiment. However, financial metrics like high debt and low ROE/ROA suggest potential risks, balancing the overall positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100